Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in severe hypercholesterolaemia

REFERENCES

• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.
   PubMed Web of Science ®Google Scholar
• Libby P. Atherosclerosis: the new view. Sci Am 2002; 286: 46–55.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43.
   PubMed Web of Science ®Google Scholar
• Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995–8.
   PubMed Web of Science ®Google Scholar
• IllingworthD.3-hydroxy-3-methylglutaryl-coenzyme. A reductase inhibitor. In: Betteridge DJ, Illingworth DR, Shepherd J, editors. Lipoproteins in health and disease: Arnold; London 1999. p. 1161–79.
   Google Scholar
• Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543–59.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of cor-onary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–44.
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230–5.
   Google Scholar
• Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000; 32: 579–83.
   Google Scholar
• van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AFH, Kastelein JJP. Differential hs-CRP reduction in patients with familial hyper-cholesterolemia treated with aggressive or con-ventional statin therapy. Atherosclerosis 2002; 165: 361–6.
   Google Scholar
• Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells syn-thesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990; 136: 1229–33.
   PubMed Web of Science ®Google Scholar
• Ikeda U, Matsui K, Murakami Y, Shimada K. Monocyte Chemoattractant protein-1 and coron-ary artery disease. Clin Cardiol 2002; 25: 143–7.
   PubMedGoogle Scholar
• Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptor reveals alter-native splicing of the carboxy-terminal tails. Proc Natl Acad Sci USA 1994; 91: 2752–6.
   PubMed Web of Science ®Google Scholar
• Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-l-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 1998; 18: 1983–91.
   PubMed Web of Science ®Google Scholar
• Han KH, Han KO, Green SR, Quechenberger O. Expression of the monocyte chemoattactant protein-1 receptor CCR2 is increased in hyper-cholesterolemia: differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999; 40: 1053–63.
   PubMedGoogle Scholar
• Boring L, Gosling J, Chensue SW, Kunkel SL, Jr RVF, Broxmeyer HE, Charo IF. Impared moncyte migration and reduced type 1 (Th 1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100: 2552–61.
   Google Scholar
• Gossling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Inv 1999; 103: 773–8.
   PubMedGoogle Scholar
• Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p. 2863–913
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
   Google Scholar
• Yld-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemo-attractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252–6.
   Google Scholar
• Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholestero-lemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001; 159: 27–33.
   Google Scholar
• Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194–9.
   Google Scholar
• Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atornas-tatin on inflammatory markers in plasma. J Intern Med 2002; 251: 338–47.
   PubMed Web of Science ®Google Scholar
• Bottiger LE, Carlson LA, Ekelund LG, Olsson AG. Raised erythrocyte sedimentation rate in asympto-matic hyperlipidaemia. Br Med J 1973; 23: 681–4.
   Google Scholar
• Pasceri V, Willerson JT, Yeh ETH. Direct Proinflammatory Effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–8.
   Google Scholar
• Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated mono-cyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531–4.
   PubMed Web of Science ®Google Scholar